A Randomized, Open-Label, Multicenter, Multinational, Dose-Ranging, Concurrent Control Study of the Safety, Efficacy, Pharmacokinetic of ENB-0040 (Human Recombinant Tissue Nonspecific Alkaline Phosphatase Fusion Protein) in Adolescents and Adults With Hypophosphatasia (HPP)

Trial Profile

A Randomized, Open-Label, Multicenter, Multinational, Dose-Ranging, Concurrent Control Study of the Safety, Efficacy, Pharmacokinetic of ENB-0040 (Human Recombinant Tissue Nonspecific Alkaline Phosphatase Fusion Protein) in Adolescents and Adults With Hypophosphatasia (HPP)

Completed
Phase of Trial: Phase II

Latest Information Update: 15 May 2017

At a glance

  • Drugs Asfotase alfa (Primary)
  • Indications Hypophosphatasia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Alexion Pharmaceuticals
  • Most Recent Events

    • 15 May 2017 According to an Alexion Pharmaceuticals media release, results were were presented at the European Calcified Tissue Society (ECTS) Congress.
    • 15 May 2017 Results from this study published in an Alexion Pharmaceuticals Media Release.
    • 04 Apr 2017 Results of 6 minute walk test from 2 phase 2 trials (n=23, NCT00952484 and NCT01163149) presented at The 99th Annual Meeting of the Endocrine Society
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top